

METHOD FOR PRODUCING HUMAN  
INTERVERTEBRAL DISC CELLS

RECEIVED

JUN 12 2002

TECH CENTER 1600/2900



BACKGROUND OF THE INVENTION

This invention relates to a method for producing human intervertebral disc cells. More particularly, this invention relates to methods for growing intervertebral cells in monolayers cultures followed by three-dimensional growth of cells.

In spite of the large health care costs associated with degenerative disc disease, the cell biology of the human intervertebral disc cell has been neglected compared to the knowledge available on chondrocytes or bone cell populations. Recent studies have presented data on the formation and turnover of matrix *in situ* in the human disc. Antoniou, J., Steffen, T., Nelson, F., Winterbottom, N., Hollander, A.P., Poole, R.A., Aebi, M., Alini, M., "The human lumbar intervertebral disc-Evidence for changes in the biosynthesis and denaturation of the extra cellular matrix with growth, maturation, ageing, and degeneration," *J. Clin. Invest.* 98, 996-1003 (1996). Growth of the young disc showed active matrix formation and denaturation of Type II collagen; aging and maturation were associated with decreased matrix synthesis and reduced denaturation of Type II collagen. Degenerative stages showed decreased aggrecan and Type II procollagen formation and increased Type II denaturation and Type I collagen synthesis. Successful isolation and *in vitro* growth of disc cells under experimental conditions can be a valuable tool for clarification of the cellular mechanisms involved in these observed matrix changes.

Studies of human disc cells cultured in alginate beads have provided evidence that more than one distinctive cell population resides in the disc.

Chelberg, M.K., Banks, G.M., Geiger, D.F., Oegema,  
T.R., "Identification of heterogeneous cell populations  
in normal human intervertebral disc," *J Anat*, 186, 43-  
53 (1995). Others have used the alginate bead technique  
5 to study canine disc cells in culture. Maldonado,  
B.A., Oegema, T.R., "Initial characterization of the  
metabolism of intervertebral disc cells encapsulated in  
microspheres," *J Orthopaedic Res*, 10, 677-690 (1992).  
Cells from the rat disc have been grown in monolayer  
10 culture. Ichimura, K., Tsuji, H., Matsui, H.,  
Makiyama, N., Cell culture of the intervertebral disc  
of rats: Factors influencing culture, proteoglycan,  
collagen, and deoxyribonucleic acid synthesis," *J*  
*Spinal Disorders*, 4, 428-436 (1991).

15 Three-dimensional cell culture is a preferred  
culture method for chondrocytes, a cell type similar to  
at least some members of the disc cell population, and  
is known to de-differentiate in monolayer culture and  
reexpress a characteristic Type II collagen  
20 extracellular matrix production when placed in agarose  
culture. Benya, P.D., Shaffer, J.D., "Dedifferentiated  
chondrocytes reexpress the differentiated collagen  
phenotype when cultures in agarose gels," *Cell*, 30,  
215-224 (1982).

25 It is an object of the present invention to  
produce human intervertebral cells in monolayer explant  
cultures.

Another object of the present invention is to  
produce human intervertebral cells in a three-  
30 dimensional cultures.

#### SUMMARY OF THE INVENTION

It has been found the human intervertebral cells may be grown and implanted into individuals with idiopathic scoliosis, herniated disc, degenerative disc disease, recurrent disc herniation or spinal stenosis.

5 Healthy specimens are obtained from the patient by either direct or percutaneous routes by a physician.

In a first embodiment of the present invention intervertebral healthy cells from a patient are grown into primary cell cultures in the presence of  
10 a cell stimulant such as a growth factor, or a cytokine or a bioactive agent to form monolayer primary cell cultures. In the case of a growth factor, fetal bovine serum is preferred as it improves cell proliferation and production of appropriate extracellular matrix  
15 components. The explant is first preferably grown on a nylon mesh anchor which simplifies feeding; cell are then expanded to larger numbers in monolayer culture.

In a second embodiment, the monolayer primary cell cultures may be seeded into alginate or agarose  
20 and fed again with the cell stimulant until three-dimensional cell cultures are formed. The cells are recovered from the alginate or agarose. Re-implantation into a site of disc degeneration is carried out using bioresorbable carriers or by placing  
25 cells directly in a disc.

#### BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a schematic illustration of the process of the present invention;

30 Figure 2A is a phase-contrast photomicrograph of cells growing from a disc explant fragment onto a nylon mesh (X130);

Figure 2B is a scanning electron micrograph of cells spreading and extending processes onto the mesh (bar at the upper left, 10  $\mu$ m);

Figure 3A shows cells grown in a three-  
5 dimensional environment;

Figure 3B is an electron microscopic examination of matrix material;

Figure 4 is a photomicrograph of immunohistochemical localization of extracellular  
10 matrix products around first passage cells grown in agarose from a 24-year old normal subject;

Figure 5A presents pooled data for Type I collagen and Type II collagen; and

Figure 5B presents pooled data for 4-S  
15 chondroitin sulfate and keratin sulfate.

#### DETAILED DESCRIPTION OF THE INVENTION

The present invention now will be described more fully hereinafter with reference to the  
20 accompanying drawings, in which preferred embodiments of the invention are shown. This invention may, however, be embodied in many different forms and should not be construed as limited to the embodiments set forth herein; rather, these embodiments are provided so  
25 that this disclosure will be thorough and complete, and will fully convey the scope of the invention to those skilled in the art.

The present invention is directed to a method for producing human intervertebral cells which are  
30 intended for implantation into a patient. It is important that the cells implanted into the patient be grown from the patient's own cells. The present

invention in one embodiment provides growing intervertebral cells by feeding with a cell stimulant or merely using an expanded number of cells from monolayer explant culture (primary culture). In  
5 another embodiment, this invention provides seeding cells from the primary culture into three-dimensional growth environments of alginate or agarose and continued feeding or without with a cell stimulant. As shown in Figure 1, disc tissue is surgically removed  
10 from a normal disc of a patient, the cells expanded by feeding with a cell stimulant on a plastic mesh such as a nylon mesh, grown in a three-dimensional microenvironment with cell stimulants such as growth factors and bioactive agents to re-express phenotype,  
15 placed in a carrier material or injected as a cell suspension and inserted into a site with disc degeneration in that same patient.

**Production Of a Monolayer Culture (Primary Culture)**

20 Disc tissue is derived from surgical disc procedures performed on individuals with idiopathic scoliosis, herniated disc, degenerative disc disease, recurrent disc herniation or spinal stenosis and the like. Healthy disc tissue may be obtained by any of  
25 the known surgical procedures and placed in a sterile medium and incubated with fungizone as a precaution against contamination. The healthy disc tissue is rinsed with phosphate buffered saline. Regions of annulus and nucleus are visually identified and  
30 representative pieces of annulus and nucleus are dissected. Those designated for culturing cells are further examined and any cartilaginous or vascular

regions are carefully removed. The disc tissue to be cultured is minced into 1-2 mm square pieces, again rinsed with saline to remove clots or residual debris, placed into culture dishes and anchored by placement of  
5 a sterile nylon mesh over the minced explant. Use of the nylon mesh anchoring technique for explants not only simplifies the feeding of cultures by anchoring fragments and thus preventing loss of fragments during cell feeding, but also provides a substrate for cell  
10 outgrowth.

To the designated cells is added Minimal Essential Medium (MEM, Gibco) with Earle's salts, 1% L-glutamine, 1% non-essential amino acids, 1% penicillin-streptomycin and about 20% (v/v) of a cell stimulant,  
15 such as a growth factor, or a cytokine or a bioactive agent. Fetal calf serum and fetal bovine serum (Gibco, Grand Island, N.Y.) are preferred. Other cell stimulants include, for example, transforming growth factor beta (TGF- $\beta$ ), insulin-like growth factor I,  
20 insulin-like growth factor II, basic fibroblast growth factor, acidic fibroblast growth factor, platelet-derived growth factor, serum, insulin, human recombinant bone morphogenetic protein 2, Vitamin D, 1,25-dihydroxyvitamin D, and other forms of bone  
25 morphogenetic protein or ITS (insulin-transferrin-selenium). Serum may or may not be present during feeding with the cell stimulant. Cells may also be grown in the Hams medium with addition of previously mentioned agents.

30 The primary cultures are grown at a temperature between about 30EC. and about 50EC.,

preferably at 37EC. Normally, the primary cultures are grown at high humidity conditions under a blanket of CO<sub>2</sub>. These cultures are fed with the cell stimulant every two days. When primary cultures show a confluent  
5 outgrowth of cells from the nylon mesh, the cultures are trypsinized. It has been found that cell viability may average 96% on a monolayer culture.

### Three-Dimensional Cell Growth

10 Following trypsinization, cells established in monolayer primary cultures may be seeded in alginate or agarose. Trypsinized cell cultures are assayed for cell viability and the required volume of cell suspension centrifuged and the medium aspirated off.

15 Regarding alginate, an alginate solution may be prepared by mixing a 1.2% solution of Keltone LV alginate (Kelco, San Diego, California) in 0.9% physiological saline and then sterilized. An appropriate volume of the sterile alginate solution is  
20 added to attain the desired cell/alginate suspension.

The three-dimensional cell structures are grown in multiwell plates. Inserts are placed in the bottom of each well. One type of insert that may be used is a Costar Transwell Clear Insert (Costar,  
25 Cambridge, Massachusetts). The alginate/cell suspension is added to the insert.

After the alginate/cell suspension is in place, a polymerizing solution is added to the well. The polymerizing solution may be one having a divalent  
30 cation. A preferred polymerizing solution is CaCl<sub>2</sub>. The alginate/cell suspension is incubated in the polymerizing solution for four minutes and the solution



aspirated out. Wells were rinsed with MEM with 20% FBS. The rinsing volume is allowed to stand for one minute, aspirated off, and the wells filled with MEM and cell stimulant (as described above) and regularly  
5 fed. Methods for disc cell growth in alginate are a modification of the methods described in Maldonado, B.A., Oegema, T.R., "Initial characterization of the metabolism of intervertebral disc cells encapsulated in microspheres," *J Orthopaedic Res*, 10, 677-690 (1992)  
10 and Guo, J., Jourdian, G.W., MacCallum, D.K., "Culture and growth characteristics of chondrocytes encapsulated in alginate beads," *Conn Tiss Res* 19:227-297 (1989).

The cells are recovered from alginate by rinsing with NaCl followed by addition of a dissolving  
15 buffer, incubated until the alginate is dissolved, centrifuged and rinsed again with NaCl. Cells are similarly recovered from agarose and other carrier types, as required. These cells, grown in this manner, may be implanted into the patient's disc using sterile,  
20 surgical direct or percutaneous techniques with placement of cells or cells on their carriers into regions selected by the surgeon. This may or may not be preceded by direct or percutaneous debridement of diseased tissue areas. Methods for re-implantation  
25 into the disc include, but are not limited to, use of cells in alginate, bioresorbable collagen substrates, and other resorbable carriers.

#### EXAMPLE 1

30 This example illustrates the growth of healthy disc cultures. Healthy disc tissue was obtained and rinsed with phosphate buffered saline at

pH 7.4. The tissue was placed in modified Minimal Essential Medium (MEM) with Earle's salts (MEM, Gilco, Grand Island, N.Y.) with 1% (v/v) L-glutamine (Irvine Scientific, Santa Ana, California), 1% (v/v)

5 penicillin-streptomycin (Irvine Scientific, Santa Ana, California), but without added serum. The disc tissue was incubated in three 15-minute rinses of MEM with 1% fungizone (Irvine Scientific) as a precaution against contamination of the cells during removal.

10 Regions of annulus and nucleus were visually identified and representative pieces of annulus and nucleus were dissected. Cartilaginous and vascular regions removed from tissue designated for culturing. The disc tissue to be cultured was minced with a  
15 scalpel into 1-2 mm square pieces, again rinsed twice with saline to remove clots or residual debris, placed into 35 mm culture dishes and anchored by placement of a sterile nylon mesh (Spectra Mesh, Spectra Laboratory Products) over the minced explant to provide a  
20 substrate for cell outgrowth.

A series of cultures were fed with varying amounts of cell stimulant. Minimal Essential Medium (MEM, Gibco) with Earle's salts and about 20% (v/v) of fetal bovine serum (FBS, Gibco, Grand Island, N.Y.) was  
25 added to the minced explant. The primary cultures were grown at a temperature of 37EC. and 95% humidity under a blanket of 5% CO<sub>2</sub>. The primary cultures are fed with fetal bovine serum every two days.

Disc cells from both the annulus and nucleus  
30 grew well on the mesh lattice. Cells from the disc grew slowly even in the presence of high (20%) FBS. Cells usually required up to a month from initiation of

explants until P1 cultures could be established.  
Doubling time in the presence of 10% FBS was 6.2 days;  
in 20% FBS, 3.4 days, and in 25% FBS, 3.5 days. Cell  
viability, determined by trypan blue exclusion,  
5 averaged 96% on monolayer culture. A phase-contrast  
photomicrograph of cells growing out from a disc  
explant fragment onto a nylon mesh (X130) is shown in  
Figure 2A. In Figure 2B there is shown a scanning  
electron micrograph of cells spreading and extending  
10 processes onto the mesh.

When primary cultures showed a confluent  
outgrowth of cells from the nylon mesh, cultures were  
trypsinized (1:250, trypsin (0.5 g/l), EDTA (0.2  
g/l)) (Irvine Scientific, Santa Ana, California) and a  
15 split ration of 1:4 used for further culturing.

## EXAMPLE 2

In this example, primary cell cultures were  
grown in alginate. Cells established in monolayer  
20 primary culture were seeded either into alginate layers  
on inserts (P1 cultures) or continued as monolayer P1  
cultures which were subsequently split and used as the  
cell source for sequential P2, P3 or P4 passages seeded  
into alginate. Several cryofrozen cultures were thawed  
25 and expanded as P1 passages on monolayer with  
subsequent P2 and later passages seeded into alginate.

The alginate solution was prepared from a  
1.2% solution of Keltone LV alginate (Kelco, San Diego,  
California) in 0.9% physiological saline with stirring  
30 for one hour. The alginate solution was sterilized by  
filtering through a 0.2  $\mu$ m bottle top filter fitted  
onto a 100 ml sterile bottle.

Trypsinized primary cell cultures were assayed for cell viability and the required volume of cell suspension centrifuged at 500 rpm for five minutes in an IEC MP4R centrifuge and the medium subsequently aspirated off. An appropriate volume of sterile 1.2% Keltone LV alginate solution was added to attain the desired cell/alginate suspension. Cells were mixed in the alginate by gentle thorough pipetting.

Costar Transwell Clear Inserts (Costar, Cambridge, Massachusetts) were placed in multiwell plates, and the desired amount of alginate/cell suspension was carefully added to the bottom of the insert well without formation of air bubbles. A correctly prepared insert showed a fully covered filter with a meniscus formed in the insert. For a 24 well plate 50  $\mu$ L of alginate/cell suspension was added to each insert. After the alginate/cell suspension was in place, each insert was carefully lifted with sterile forceps and the desired volume of 102 mM  $\text{CaCl}_2$  polymerizing solution was added to the well. This volume covered the bottom of the filter, but was not enough to allow the  $\text{CaCl}_2$  solution to enter into the insert. The inserts were incubated in  $\text{CaCl}_2$  polymerizing solution for four minutes and the solution aspirated out. Wells were rinsed with MEM with 20% FBS (2.5 mL/well for 24 well plates).

The rinsing volume filled both well and insert, was allowed to stand for one minute, and was aspirated off. Four inserts were set up for each concentration at each time point (Days 6, 8 and 10). Each well was fed with MEM supplemented with TGF-

β1) (Sigma) at the following doses: control (no TGF-β1), 0.25, 0.50, 1.0, 2.5, and 5 ng/ml. These alginate cultures were grown for ten days with feeding three times per week. Cell proliferation data, expressed as  
5 total [<sup>3</sup>H]thymidine uptake/μg DNA, were obtained on days 6, 8, and 10.

The cells were removed from the alginate by rinsing the wells twice with 0.15 M NaCl<sub>2</sub> (2.5 mL/well for 24 well plates) by lifting the insert and pipetting  
10 into the well. The rinse solution was incubated for one minute, and was aspirated off via the solution under the insert. The solution within the insert was not aspirated off. After the second rinse, the remaining liquid from the insert was wicked off by  
15 gently touching a twisted sterile gauze square to the side of the tipped well. Three times the volume of the alginate in dissolving buffer (55 mM sodium citrate and 0.15 M NaCl<sub>2</sub>) was added to the inside of the insert and plates incubated at 37EC. for ten minutes with shaking.  
20 Contents of the insert were gently pipetted to ensure complete dissolution of the alginate.

At the end of ten days, medium was withdrawn and cultures fixed with 1% neutral buffered formalin for five minutes, the insert carefully cut from the  
25 plastic holder and wrapped gently in lens paper, placed in a tissue cassette in 70% ethanol and processed using the short cycle run on a paraffin processor (Shandon Lipshaw Hypercenter XP, Pittsburgh, Pennsylvania). Morphologic studies of cells grown in these three-  
30 dimensional microenvironments show that cells lay in a lacunar space with matrix deposited between and around

the disc cells (Figure 3A). Electron microscopic examination revealed that matrix material consisted of proteoglycans and banded and non-banded collagen (Figure 3B).

5

### EXAMPLE 3

Adjacent sections of three-dimensional cultures from Example 2 cut *en face* were collected and utilized for immunohistochemical localization of rabbit  
10 anti-human collagen Type I or rabbit anti-human collagen Type II (Biodesign International, Kennebunk, Maine), monoclonal anti-proteoglycan delta DI-4S (ICN, Costa Mesa, California) or monoclonal anti-keratin sulfate (Seikagaku Corp., Tokyo, Japan).

15 Negative controls were incubated minus primary antibodies. Localization utilized DAB colorimetric visualization of extracellular matrix constituents. Cells or colonies were scored for positive immunohistochemical localizations using a  
20 Nikon microscope (20X objective) and OsteoMeasure computer software (OsteoMetrics, Inc., Atlanta, Georgia). The mean number of cells or colonies assessed for each localization was: Type I collagen: 272; Type II collagen: 260; proteoglycan delta DI-4S,  
25 241, and keratin sulfate, 201. Nine surgical and two normal series of cells were studied in this experiment. Passages 1 through 4 were evaluated for cells from one specimen and one normal; passage number 3 was studies for normal; passages 1 through 3 for two specimens;  
30 passages 2 through 3 from three specimens; passages 2 through 4 in one, and passages 2 through 5 in two specimens. Figures 5A and 5B show the proportion of

colonies positive for the presence of Type I or Type II collagen, 4-5 chondroitin sulfate or keratin sulfate.

### **Statistical Analysis**

5                   Data are presented as mean  $\bar{V}$  s.e.m. SAS7  
(version 6.11, SAS Institute, Inc., Cary, North  
Carolina) software was utilized for data analysis.  
Standard statistical methods were employed. Paired t-  
test were used to compare means of frozen and non-  
10 frozen matrix scoring. To detect potential bias  
between frozen and non-frozen groups with respect to  
both passage 2 and passage 3 results (examined  
separately), unpaired t-tests were used. A repeated  
measures analysis of variance was performed to test for  
15 differences over time (passages 2, 3 and 4). All tests  
were two-sided, and p-values  $\leq .05$  were considered  
statistically significant.

### **Immunohistochemical Characterization of Cells Grown in Alginate and Quantitative Scoring of Matrix in Cells and Colonies**

20                   Cells from the annulus were characterized  
using sequential passages of cells seeded into alginate  
over passages 1 through 5. Representative micrographs  
25 showing localization of Type I or Type II collagen or  
proteoglycan D1-4S or keratin sulfate are shown in  
Figure 4. The micrographs illustrated in Figure 4 show  
sequential serial sections with localizations of types  
I, II, III, and VI collagen, 4-S-chondroitin sulfate,  
30 and Keratin sulfate. Positive immunoreactivity is  
shown by dark staining DAB reaction product (X100).

As shown in Table 1, both non-frozen and

cryo-frozen cells have been analyzed in the present study. Table 1 presents data which were analyzed by paired t-tests since the same cultures were followed through sequential passages. There were no  
5 statistically significant differences in the mean percentages of frozen and non-frozen cells with respect to the various extracellular matrix components.



**Table 1. Summary of Quantitative Cell/Colony Scoring of Immunolocalized Extracellular Matrix Components in Non-Frozen and Frozen Cultures\***

	Passage 1	Passage 2**	Passage 3***
<b>Non-Frozen Cultures:</b>			
Type I Collagen (n=4)	94.7V2.7	96.3V1.2	97.3V1.0
Type II Collagen (n=4)	85.3V1.6	82.5V4.0	86.6V1.6
Proteoglycan delta DI-4S (n=4)	89.4V2.8	85.5V1.6	93.8V4.3
Keratin sulfate (n=4)	82.9V5.3	84.8V2.1	86.0V3.3
<b>Frozen Cultures:</b>			
Type I Collagen	--	93.3V1.0	94.0V3.8
Type II Collagen	--	87.5V2.2	92.0V2.0
Proteoglycan delta DI-4S	--	91.9V2.2	94.4V2.3
Keratin sulfate	--	82.4V3.3	86.2V2.9

5 \* Data are mean  $\pm$  V s.e.m. The total number of colonies or cells scored in each analysis ranged from 201 to 272.

\*\* n=6 for P2 for frozen cultures

\*\*\* n=7 for P3 for frozen cultures

Figure 5 presents pooled data for frozen and non-frozen cells studied from passages 1 through 5. These data were also evaluated using paired t-tests of passages 2 and 3 and of 2 and 4, respectively. There were no statistically significant differences between the mean of passage 2 and those of both passage 3 and 4, with respect to Type I collagen, Type II collagen and keratin sulfate. Passage 3 was found to have a significantly higher (p=.02) mean incidence of proteoglycan D1-4S than did passage 2.

A repeated measures analysis of variance was also applied to the data in Figure 5 which used five observations (data for all of passages 2, 3 and 4). No statistically significant changes over the course of passages 2, 3 or 4 were identified for the incidence of

the four extracellular matrix components studied.

Many modifications and other embodiments of the invention will come to mind to one skilled in the art to which this invention pertains having the benefit  
5 of the teachings presented in the foregoing descriptions and the associated drawings. Therefore, it is to be understood that the invention is not to be limited to the specific embodiments disclosed and that modifications and other embodiments are intended to be  
10 included within the scope of the appended claims. Although specific terms are employed herein, they are used in a generic and descriptive sense only and not for purposes of limitation.

THAT WHICH IS CLAIMED:

1. A method for producing human intervertebral cells comprising:
  - (a) providing annulus or nucleus disc cells of human origin;
  - (b) subjecting said disc cells to a cell stimulant from the group consisting of a growth factor, a cytokine, a bioactive agent and serum until primary cell cultures are grown to form a primary cell culture; and
  - (c) recovering said primary cells having the natural cell structure of the starting cells for implanting into a patient.
2. The method of Claim 1 wherein said cell stimulant is selected from the group consisting of fetal bovine serum, transforming growth factor beta, insulin-like growth factor I, insulin-like growth factor II, basic fibroblast growth factor, acidic fibroblast growth factor, platelet-derived growth factor, serum, insulin, human recombinant bone morphogenetic protein 2, ITS (insulin-transferrin-selenium) and other forms of bone morphogenetic protein.
3. The method of Claim 1 wherein said member is fetal bovine serum.
4. The method of Claim 1 where said cells are grown at a temperature of 30EC. and 50EC. and fed every two days.

5. The method of Claim 1 wherein said disc tissue is obtained from the region of the annulus.

6. The method of Claim 1 wherein said disc tissue is obtained from the region of the nucleus.

7. The method of Claim 1 wherein a mesh is placed over said disc cells prior to subjecting said disc cells to said cells stimulant.

8. The method of Claim 1 wherein said primary cell culture is seeded in alginate and treated with a polymerization solution.

9. The method of Claim 8 wherein said polymerization solution is  $\text{CaCl}_2$ .

10. The method of Claim 1 wherein said primary cell culture is seeded in agarose and treated with a polymerization solution.

11. The method of Claim 10 wherein said polymerization solution is  $\text{CaCl}_2$ .

12. A method for producing human intervertebral cells comprising:

(a) providing annulus or nucleus disc cells of human origin;

(b) subjecting said disc cells to a cell stimulant from the group consisting of fetal bovine serum, transforming growth factor beta, insulin-like

growth factor I, insulin-like growth factor II, basic fibroblast growth factor, acidic fibroblast growth factor, platelet-derived growth factor, serum, insulin, human recombinant bone morphogenetic protein 2, ITS (insulin-transferrin-selenium) and other forms of bone morphogenetic protein at a temperature of 30EC. and 50EC. and fed every two days;

(c) seeding primary cell culture in alginate and treating with a polymerization solution to form a three dimensional structure of cells; and

(d) recovering said three-dimensional cell structure having the natural cell structure of the starting cells for implanting into a patient.

13. A method for treating intervertebral disc disease or disc injury in human, comprising:

providing a normal human intervertebral disc specimen;

obtaining a minced explant comprising annulus or nucleus cells from said human intervertebral disc specimen;

propagating the annulus or nucleus cells in cell culture; and

implanting the propagated cells into a targeted area in a human disc needing treatment.

14. The method of Claim 13, wherein said minced explant is in about 1-2 mm square pieces.

15. The method of Claim 13, wherein the annulus or nucleus cells are propagated in the presence

of a cell stimulant selected from the group consisting of fetal bovine serum, growth factors, and cytokines.

16. The method of Claim 13, wherein said step of propagating the annulus or nucleus cells comprises:

placing said minced explant in a cell culture dish and covering the explant with a sterile nylon mesh;

growing said explant into a monolayer of cells; and

splitting said monolayer of cells for further propagation.

17. The method of Claim 13, wherein said disc specimen is obtained surgically from the human to be treated.

18. The method of Claim 13, wherein said implanting step comprises:  
debriding the diseased or injured tissue; and  
delivering said propagated cells into the area of debridement.

19. The method of Claim 15, wherein said growth factor is selected from the group consisting of transforming growth factor beta, insulin-like growth factor I, insulin-like growth factor II, basic fibroblast growth factor, acidic fibroblast growth factor, platelet-derived growth factor, insulin, bone morphogenetic proteins, and ITS (insulin-transferrin-selenium).

20. The method of Claim 16, wherein said step of propagating the annulus or nucleus cells further comprises:

seeding cells from said monolayer into a three-dimensional structure; and

growing said seeded cells to form a three-dimensional cell structure.

21. The method of Claim 20, wherein said three-dimensional cell structure is formed in a cell well insert.

22. The method of Claim 20, wherein said three-dimensional structure is formed with alginate.

23. The method of Claim 20, wherein said three-dimensional structure is formed with agarose.

24. The method of Claim 20, wherein said three-dimensional structure is formed with collagen.

25. The method of Claim 20, wherein said three-dimensional cell structure is implanted into the target area.

26. A method for treating intervertebral disc disease or disc injury in a human, comprising:

removing surgically a normal intervertebral disc specimen from said human;

obtaining a minced explant in comprising annulus or nucleus cells from said disc specimen;

placing said minced explant in a cell culture dish and covering the explant with a sterile nylon mesh;

growing said explant into a monolayer of cells;

seeding cells from said monolayer into a three-dimensional structure of alginate in a cell well insert placed in a well;

growing said seeded cells to form a three-dimensional cell structure;

recovering cells from said three-dimensional cell structure; and

implanting the recovered cells into a targeted area in the human needing treatment.



ABSTRACT

There is provided a method for growing human intervertebral cells. Disc tissue is surgically removed from a normal disc of a patient, the cells expanded by feeding with a cell stimulant such as a growth factor, or a cytokine or a bioactive agent to form monolayer primary cell cultures on a plastic mesh such as a nylon mesh. In the case of a growth factor, fetal bovine serum is preferred as it improves cell proliferation and production of appropriate extracellular matrix components. In another aspect of this invention, the monolayer primary cell cultures are seeded in alginate or agarose and fed again with the cell stimulant until three-dimensional cell cultures are formed. The cells are recovered from the alginate or agarose or from monolayer cultures. Re-implantation is carried out using bioresorbable carriers or cell suspensions.

CLT01/4280445v1

CLT01/4280445v1